BridgeMD
New treatment option for Prostate Cancer Surgery
Official title Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
ClinicalTrials.gov ID: NCT06776172
What this study is testing
- What it's testing
- The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.
- Time commitment: about 10 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Age ≥ 18 years and life expectancy \>15 years
- Any biopsy-proven WHO/ISUP grade groups III-V PCa
- High-risk prostate cancer defined as:
- Any biopsy-proven WHO/ISUP grade group III-V PCa or
- ISUP grade group II and PSA \> 20 ng/ml
You likely can't join if
- ISUP grade group I PCa and cT1 or cT2 (MRI)
- cT4 (MRI) PCa
- PSMA-PET: positive staging for local and distant metastasis
- Any prior neoadjuvant, local or systemic treatment for PCa
- Previous PLND or pelvic radiotherapy
- Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years...
See the full eligibility criteria
- Age ≥ 18 years and life expectancy \>15 years
- Any biopsy-proven WHO/ISUP grade groups III-V PCa
- High-risk prostate cancer defined as:
- Any biopsy-proven WHO/ISUP grade group III-V PCa or
- ISUP grade group II and PSA \> 20 ng/ml
- PSMA-PET: negative staging for regional and distant metastasis
- multidisciplinary tumorboard recommendation for radical prostatectomy
- WHO performance status 0-1
- Adequate condition (ASA ≤ III) for general anesthesia and RP
- ISUP grade group I PCa and cT1 or cT2 (MRI)
- cT4 (MRI) PCa
- PSMA-PET: positive staging for local and distant metastasis
- Any prior neoadjuvant, local or systemic treatment for PCa
- Previous PLND or pelvic radiotherapy
- Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at...
- Any other serious underlying medical, psychiatric, psychological, familial, or geographical
- condition, which in the judgment of the investigator may interfere with the planned
- staging, treatment and follow-up, which affect patient compliance or place the patient at
- high risk from treatment-related complications.
- Vulnerable men (participants incapable of judgment or participants under tutelage) will not be included in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Aarau, Switzerland
- Basel, Switzerland
- Bern, Switzerland
- Biel, Switzerland
- Chur, Switzerland
- Geneva, Switzerland
- Lausanne, Switzerland
- Liestal, Switzerland
- Lucerne, Switzerland
- Lugano, Switzerland
- Neuchâtel, Switzerland
- Sankt Gallen, Switzerland
- Zurich, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 10 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aarau, Switzerland; Basel, Switzerland; Bern, Switzerland; Biel, Switzerland; Chur, Switzerland; Geneva, Switzerland and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.